Matinas BioPharma Holdings, Inc. (MTNB) Fair Value 2026

MTNB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Matinas BioPharma Holdings, Inc. (MTNB) trades at $0.20, versus a $0.42 median fair value across its 2 active models — 108.9% above the current price. QOC: 4.1/10. Value Trap Risk: 35/100 (LOW). 2/13 models active.

Key Facts

Ticker
MTNB
Price
$0.20
Quality Score
4.1/10
Value Trap Risk
35/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +227.5% upside with 47% confidence
Risk: Below-average Quality Score of 4.1/10 signals weak fundamentals

Is Matinas BioPharma Holdings, Inc. (MTNB) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Matinas BioPharma Holdings, Inc. (MTNB) appears undervalued as of : the median of 2 independent fair value estimates is $0.42, 108.9% above the current price of $0.20. Estimates range from $0.18 to $0.65. MTNB scores 4.1/10 on fundamental quality and 35/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. MTNB’s +108.9% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Matinas BioPharma Holdings, Inc. Stock in 2026? →

What Fair Value Does Each Model Give MTNB?

2 Intrinsic Value Models vs. Current Price ($0.20)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.65 +227.5%
Option-Based · Medium Conviction
 $0.18 -9.7%

All Models Active

All 2 models are displayed above.

What Is Matinas BioPharma Holdings, Inc. (MTNB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Matinas BioPharma Holdings, Inc. presents a highly debated valuation profile at its current price of $0.20. The median intrinsic value is estimated at $0.42 (+108.9% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: ML-RIV targets $0.65 (+227.5%), versus PWERM at $0.18 (-9.7%). This +237.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About MTNB?

2 of 13 models are currently active for MTNB. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for MTNB is $0.42 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does MTNB Rank in Biotechnology?

Among 625 Biotechnology stocks, MTNB ranks #520 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Matinas BioPharma Holdings, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating MTNB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is MTNB a Value Trap?

CirclFi's Value Trap algorithm assigns MTNB a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Matinas BioPharma Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Matinas BioPharma Holdings, Inc.'s fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +237.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MTNB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MTNB's 2 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Matinas BioPharma Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

TVRDTvardi Therapeutics, Inc.QOC 4.1GRIGRI Bio, Inc.QOC 4.1GTBPGT Biopharma, Inc.QOC 4.1XRTXXORTX Therapeutics Inc.QOC 4.1ARMPArmata Pharmaceuticals, Inc.QOC 4.1MTVAMetaVia Inc.QOC 4.1GMABGenmab A/SQOC 6.9DNTHDianthus Therapeutics, Inc.QOC 5.6APREAprea Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: TVRD · GRI · GTBP · XRTX · ARMP · MTVA · GMAB · DNTH · APRE · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MTNB?

6 companies across all industries closest to MTNB’s Quality of Company score of 4.1/10.

MITIMitesco, Inc.QOC 4.1DXFEason Technology LimitedQOC 4.1VYNDVynleads, Inc.QOC 4.1AIHSSenmiao Technology LimitedQOC 4.1ARRTArtisan Consumer Goods, Inc.QOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MITI · DXF · VYND · AIHS · ARRT · NVDA

Where Does MTNB Sit in CirclFi's Biotechnology Rankings?

MTNB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Matinas BioPharma Holdings, Inc.’s Valuation?

What is Matinas BioPharma Holdings, Inc.'s intrinsic value in 2026?

CirclFi puts Matinas BioPharma Holdings, Inc. (MTNB)'s intrinsic value at $0.42 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.18 to $0.65. The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MTNB overvalued or undervalued right now?

At $0.20, 1 of 2 active models suggest MTNB may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $0.42, 108.9% above the current price of $0.20 — a consensus view that MTNB is undervalued. The assessment depends on which methodology best fits Matinas BioPharma Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for MTNB?

Matinas BioPharma Holdings, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MTNB?

CirclFi analyzes MTNB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is MTNB a value trap in 2026?

Matinas BioPharma Holdings, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Matinas BioPharma Holdings, Inc. (MTNB) has a median fair value of $0.42 — 108.9% above the current price of $0.20 — as of 2026-08-28.” Source: circlfi.com/stock/MTNB/ · Methodology
Primary sources for this MTNB valuation
  • Financial statements: Matinas BioPharma Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001582554) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MTNB as of ; valuations recomputed .